Viralytics on track with IV delivery
Wednesday, 25 June, 2008
Viralytics (ASX: VLA) has completed the first step of phase I clinical trials of its oncolytic virus technology, Cavatrak, for stage IV metastatic melanoma.
The safety trial involved each subject receiving an intravenous injection of Cavatrak. No adverse effects were found in the test subjects, the company said.
Viralytics has also been granted clearance to continue the trials with the next patient group. This cohort will receive two injections of the drug seven days apart.
This trial is being run concurrently with another set of clinical trials of late-stage melanoma patients. The subjects in that trial are being given multiple intra-tumoural injections of Cavatrak in doses up to 100 times the original.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
